Canadian Severe Asthma Registry
Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the complexity of the severe asthma population, large numbers of patients need to be evaluated in order to understand the clinical features and outcomes of the condition and ultimately facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a global collaborative initiated to gather anonymous real-life data for patients with severe asthma from over 29 countries. ISAR provides the statistical power and collaborative framework to better understand severe asthma epidemiology across countries and regions so as to better address important research questions in an attempt to improve symptoms, treatments and patient outcomes for severe asthma. With a target of 13,125 patients, ISAR has currently recruited over 9,000 patients.
The Canadian Severe Asthma Registry (CSAR) is Canada’s contribution to ISAR. With leadership from the Vancouver General Hospital (VGH), the registry collects data at VGH, St. Paul’s Hospital and five additional sites in Alberta, Ontario and Quebec. The target for Canadian recruitment is 700 patients by 2023 and approximately 115 patients have so far been recruited across the 7 sites.
The CSAR enables Canadian asthma researchers and clinicians to contribute to ISAR and bolsters their ability to participate in global initiatives in severe asthma research and knowledge implementation.
Current participating CSAR sites with the corresponding principle investigator (Partners)

  • Vancouver General Hospital, Vancouver (Dr. Mark FitzGerald)
  • Paul’s Hospital, Vancouver (Dr. Del Dorscheid)
  • University of Alberta Hospital, Edmonton (Dr. Mohit Bhutani)
  • Rockview Hospital, University of Calgary, Calgary (Dr. Patrick Mitchell)
  • Inspiration Research Ltd., Toronto (Dr. Kenneth Chapman)
  • University of Institute of Cardiology & Respirology of Quebec, Laval University, Quebec City (Dr. Andréanne Coté)
  • McGill University Health Centre, Montreal (Dr. Ronald Olivenstein)